Conclusions In patients undergoing hemodialysis, the initiation of treatment with rosuvastatin lowered the LDL cholesterol level but had no significant effect on the composite primary end point of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke.
This is in line with what was known before and was the subject of my inaugural blog post in 2005.
No comments:
Post a Comment